The investigation of selective sphingosine-1 phosphate receptor 1&4 modulator to treat alopecia areata mouse model
May 2023
in “
The Journal of Immunology
”
TLDR NXC736 significantly reduced hair loss in mice with alopecia areata.
The study investigated the efficacy of a selective sphingosine-1 phosphate receptor 1 and 4 modulator, NXC736, in treating alopecia areata (AA) in a mouse model. AA is an autoimmune disease characterized by hair loss, involving NKG2D+CD8+ T cells. The study involved oral administration of NXC736 for 84 days, which resulted in a significant decrease in AA lesion area and disease-free ratio compared to the control group. Additionally, there was a notable reduction in the infiltration of CD8+ T cells and NKG2D levels in effector CD8+ T cells in the lesion skin. These findings suggest that S1PR 1 and 4 modulators could be a promising treatment for AA.